Lemtrada(Genzyme/Sanofi) superior to Rebif in CARE-MS II Multiple Sclerosis study

The Phase lll CARE-MS ll trial met both of its co-primary endpoints for Lemtrada(alemtuzumab)from Genzyme/Sanofi in the treatment of Multiple Sclerosis (MS). In this randomized trial involving 840 patients, a 49 percent reduction in relapse rate was observed in patients treated with Lemtrada 12 mg compared to Rebif ( subcutaneous interferon beta-1a) over two years of study(p<0.0001). importantly there was also a 42 percent reduction in the risk of sustained accumulation worsening of disability as measured by the expanded disability status scale.genzyme is developing alemtuzumab in ms in collaboration with bayer healthcare. lemtrada has been granted fast track designation by the fda.>